These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-000148-26 A multi-center, multinational, phase 3, open-label extension trial to assess the safety of long term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinsons disease who ar... 2008-12-19 due-trials
Reported results 2004-000152-16 An international open-label extension trial to determine safety and efficacy of long-term oral SPM 927 in patients with partial seizures 2010-08-05 due-trials
Reported results 2004-000199-14 A Double-Blind, Randomized, Multicenter, Placebo-Controlled, In-Patient, Maximum 24 Day Study of Levetiracetam Oral Solution 20-50 mg/kg/day as Adjunctive Treatment of Refractory Partial Onset Se... 2007-03-22 due-trials
Reported results 2004-000200-40 A Multi-Center, Open-Label, Long Term, Follow-Up Study of the Safety and Efficacy of Levetiracetam in Children with Partial Onset Seizures. 2008-06-24 due-trials
No trial status on register, and reported results 2004-000290-58 Estudio multicéntrico, doble ciego, aleatorizado, controlado con placebo, en grupos paralelos, para investigar la eficacia y la seguridad de SPM927 (200 mg y 400 mg/día)como tratamiento complementario... bad-data
Reported results 2004-000476-13 LONG-TERM OPEN-LABEL EXTENSION TRIAL FOR SUBJECTS COMPLETING THE PHASE 3 TRIAL OF FESOTERODINE (SP583) FOR THE TREATMENT OF OVERACTIVE BLADDER SYNDROME 2007-07-11 due-trials
Reported results 2004-000551-42 A MULTI-CENTER, OPEN-LABEL, FOLLOW-ON TRIAL TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF LACOSAMIDE IN SUBJECTS WITH PAINFUL DISTAL DIABETIC NEUROPATHY INCLUDING A DOUBLE-BLIND, RANDOMIZED TIME POIN... 2011-01-05 due-trials
Reported results 2004-000960-28 A multi-center, open-label trial to assess the long-term safety and efficacy of SPM 927 in subjects with painful diabetic neuropathy 2007-10-31 due-trials
Reported results 2004-000975-32 An exploratory, double blind, randomized, placebo-controlled, parallel group, multicenter study, for the assessment of efficacy, safety and tolerability of ucb 34714 50 mg oral capsules in b.i.d. admi... 2006-03-28 due-trials
Completed, but no date, and reported results 2004-001302-27 An 8-week exploratory, double-blind, placebo controlled, randomized trial : Evaluation of the efficacy and safety of levetiracetam up to 3000 mg/day (250-500 mg oral tablets in b.i.d. administration) ... bad-data
Listed as ongoing, but also has a completion date and reported results 2004-001339-41 A therapeutic confirmatory, open-label, multi-center, randomized 2 parallel groups, community-based trial studying the efficacy and safety of levetiracetam 1000 to 3000 mg/day oral tablets 250-500 ... 2007-10-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-001856-35 A multicenter, double-blind, randomized, placebo-controlled, 3 parallel groups, dose-ranging trial evaluating the efficacy and safety of ucb 34714 used as adjunctive treatment at doses of 50 and 150 ... 2006-04-28 bad-data
No trial status on register 2004-001928-20 Open-label, multi-centre study to compare the effectiveness of QvarTM Autohaler therapy with conventional therapy (similar doses) in children with stable asthma bad-data
Reported results 2004-001997-13 An open-label, multicenter, follow-up study to evaluate the safety and efficacy of levetiracetam (LEV) (oral tablets of 166, 250 or 500 mg b.i.d.), at individualized doses up to a maximum of 4000 mg/d... 2007-09-27 due-trials
Reported results 2004-002140-10 An open-label, multi-center, follow-up trial to evaluate long-term safety and efficacy of brivaracetam (ucb 34714) used as adjunctive treatment at a flexible dose up to a maximum of 200 mg/day in subj... 2019-05-28 due-trials
Reported results 2004-002322-22 A multi-center, open-label trial to investigate the safety and tolerability of intravenous SPM 927 as replacement for oral SPM 927 in subjects with partial seizures with or without secondary generaliz... 2006-05-10 due-trials
Reported results 2004-002598-21 A phase 3b, open-label, multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parki... 2005-07-21 due-trials
Reported results 2004-002609-66 A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impair... 2005-10-25 due-trials
Reported results 2004-002641-12 A multicenter, multinational, phase 3B, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson s disease 2008-12-16 due-trials
Reported results 2004-002650-59 A phase 3b, open-label, multicentre, multinational trial to assess the tolerability of switching subjects from ropinerole, pramipexole or cabergoline to the rotigotine transdermal system and its effec... 2005-07-06 due-trials
Reported results 2004-002823-42 A multicentre, double-blind, parallel, randomized, placebo-controlled study Evaluation of the efficacy and safety of Levocetirizine 5 mg and Desloratadine 5 mg administered orally as capsules once da... 2005-12-09 due-trials
Reported results 2004-002971-18 A monocenter, double-blind, randomized trial, with two parallel groups comparing the clinical efficacy of levocetirizine 5 mg capsules and desloratadine 5 mg capsules taken once a day over 3 weeks of ... 2005-09-22 due-trials
Reported results 2004-002993-49 A Phase III multicentre, double blind, placebo-controlled, parallel group 52-week study to assess the efficacy and safety of 2 dose regimens of lyophilised CDP870 given subcutaneously as additional me... 2006-10-28 due-trials
Completed, but no date, and reported results 2004-003858-26 A pilot, open, monocenter, randomized two parallel groups, clinical efficacy trial: Comparison continuous versus on demand regimen of treatment with Levocetirizine 5 mg oral tablets, once a day, in ad... bad-data
Reported results 2005-000358-65 A multicentre, double-blind, two parallel groups, randomized trial over four weeks of treatment to compare the clinical efficacy and safety of Levocetirizine 5 mg oral capsules once daily in the morn... 2007-01-03 due-trials
Reported results 2005-000428-18 A mulit-center, randomized, double-blind, placebo-controlled, four-arm parallel group trial to investigate the efficacy and safety of three different transdermal doses of rotigotine in subjects with i... 2006-08-23 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-000705-59 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurologic Systems 2007-03-08 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-000706-31 A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi- Center Study of Epratuzumab in Patients with Active Systemic Lupus Erythematosus 2007-02-16 bad-data
Reported results 2005-001350-24 A Phase III multi-centre, open-label, follow-on study to CDP870-027, to assess the efficacy and safety of lyophilised CDP870 an engineered human anti-TNF PEG conjugate, as additional medication to met... 2012-02-06 due-trials
Reported results 2005-001731-30 A Two-Part, Open Label Phase II Trial: Part One, Dose Escalation Safety; Part Two, Randomized/Comparing CDP791 (10 or 20 mg/kg) Plus Carboplatin/Paclitaxel With Carboplatin/Paclitaxel Alone in Subjec... 2009-06-25 due-trials
Reported results 2005-001970-29 Multinational, prospective, randomized, double-blind, placebo-controlled, parallel groups study to assess the efficacy and safety of Prostaglandin E1 in subjects with circulatory disturbance of a limb 2013-07-30 due-trials
Reported results 2005-002141-39 Multicenter, dose response, randomized, double blin, parallel, 3 arms, placebo controlled clinical trial to evaluate the efficacy and the safety of subcutaneous CDP870 (certolizumab pegol) at 2 differ... 2007-01-11 due-trials
Reported results 2005-002326-63 A Phase III Multi–center, Double–blind, Placebo–controlled, Parallel Group 24–Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication to... 2006-09-19 due-trials
Reported results 2005-002611-25 An open label extension trial to investigate the safety and tolerability of long-term treatment with transdermal rotigotine in subjects with idiopathic restless legs syndrome 2007-09-08 due-trials
Reported results 2005-002629-30 A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Liquid Certolizumab Pegol as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms a... 2012-02-09 due-trials
Reported results 2005-002814-39 A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TWO-ARM, PARALLEL-GROUP, SLEEP LAB TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF TRANSDERMAL ROTIGOTINE IN SUBJECTS WITH IDIOPATHIC RESTL... 2006-07-21 due-trials
Reported results 2005-003977-25 A phase III B multicentre open label 54 weeks clinical trial evaluating certolizumab pegol, a PEGylated Fab fragment of humanized antibody to tumor necrosis factor alpha (TNF alpha) on endoscopic and ... 2010-03-31 due-trials
Reported results 2005-004104-37 A Phase IIIb multicentre, open label induction and double blind comparison of two maintenance schedules evaluating clinical benefit and tolerability of certolizumab pegol, a PEGylated Fab' fragment of... 2008-08-07 due-trials
Reported results 2005-004290-19 A double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in subjec... 2006-06-23 due-trials
Completed, but no date, and reported results 2005-004417-15 Single center, therapeutic exploratory clinical trial to evaluate the safety of sodium oxybate (Xyrem) 500 mg/mL oral solution on potential endocrine changes at currently labeled therapeutic dose regi... bad-data
Reported results 2005-005525-63 Follow-up of study C87040 : Multicenter, single blind study to describe the efficacy and safety of re-treatment with CDP870 (certolizumab pegol) subcutaneous at 2 different dose regimens (400 mg init... 2007-06-11 due-trials
Reported results Terminated 2005-005686-11 CONFIRMATORY, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUPS STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROSTAGLANDIN E1 IN SUBJECTS WITH DRY AGE-RELATED MACULAR DEGENERATI... 2010-06-30 due-trials
Reported results 2005-005788-27 A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF 400MG/DAY LACOSAMIDE IN SUBJECTS WITH PAINFUL DISTAL DIABETIC NEUROPATHY USING TWO DIFFERENT T... 2008-06-29 due-trials
Reported results 2006-000169-12 A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patien... 2007-10-15 due-trials
Reported results 2006-000173-29 A multicenter, open-label single-arm follow-up trial evaluating the long-term safety of levetiracetam, for patients suffering from epilepsy and coming from the study N01175. 2008-04-30 due-trials
Reported results 2006-000987-10 A double-blind, placebo-controlled, randomized efficacy and safety study of levetiracetam extended release formulation (LEV XR), administered as 2 x 500 mg LEV XR tablets once daily as add-on therapy ... 2007-07-19 due-trials
Reported results 2006-001536-46 A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patien... 2008-01-08 due-trials
Reported results 2006-001729-24 Ensayo clínico abierto a largo plazo para evaluar la eficacia y seguridad del tratamiento crónico con certolizumab pegol, un fragmento Fab pegilado del anticuerpo humanizado dirigido al factor de necr... 2010-11-02 due-trials
Reported results 2006-001937-17 A randomized, double-blind, placebo-controlled, parallel-group proof-of-concept trial to assess the efficacy, safety and tolerability of ascending doses of rotigotine nasal spray for the acute treatme... 2006-11-29 due-trials
Reported results 2006-002027-16 Certolizumab pegol 400 mg monthly in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequen... 2008-08-02 due-trials
Reported results 2006-002204-33 Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two doses o... 2010-07-28 due-trials
Reported results 2006-003870-88 A Phase IIIb, multi-center, double-blind, placebo-controlled, randomized trial to examine the corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease (C... 2009-07-09 due-trials
Reported results 2006-003871-11 An open-label, multi-center trial to examine the long term safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease who have failed... 2010-02-23 due-trials
Reported results 2006-005048-97 A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF 400MG/DAY LACOSAMIDE IN SUBJECTS WITH OSTEOARTHRITIS OF THE KNEE 2007-11-20 due-trials
Reported results 2006-005438-19 An explorative, multicenter, open-label pilot trial with Neupro® (Rotigotine transdermal patch) once daily treatment administered perioperatively in Patients with idiopathic Parkinson´s disease. 2008-10-14 due-trials
Reported results 2006-005722-23 Open-label, single-arm, multi-center, pharmacokinetic, safety and tolerability study of levetiracetam intravenous infusion in children (4 - 16 years old) with epilepsy. 2010-02-02 due-trials
Reported results 2006-006344-59 A multi-center, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (>= 16 to 70 years old) with Partial Onset Seizure... 2009-02-09 due-trials
Trial is outside EEC 2006-006345-14 An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizu... bad-data
Reported results 2006-006346-34 An international, randomized, double-blind, parallel-group, placebo-controlled, flexible dose study: evaluation of the safety and efficacy of brivaracetam in subjects (>= 16 to 70 years old) sufferi... 2008-11-28 due-trials
Trial is partly outside EEC, and reported results 2006-006536-22 ESTUDIO MULTICÉNTRICO, ABIERTO, DE UN SOLO BRAZO DE TRATAMIENTO, PARA EVALUAR LA FARMACOCINÉTICA, SEGURIDAD Y EFICACIA DE LA ADMINISTRACIÓN DE BRIVARACETAM COMO TRATAMIENTO ADYUVANTE EN PACIENTES DE 1... 2013-03-13 bad-data
Reported results 2006-006752-35 PHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCT... 2009-03-09 due-trials
Reported results 2006-006907-35 A multicenter, multinational, phase 3b, open label extension trial, to evaluate the long term effect of the 24 hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal a... 2009-05-05 due-trials
Reported results 2007-000828-40 A Phase IIIB, multi-centre, double-blind randomized, placebo-controlled, parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti-TNFα Fab′ fragment, certolizumab pegol, a... 2010-12-10 due-trials
Reported results 2007-000830-38 A Phase IIIB, multi-centre open label, follow-up study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with DMARDs in subjects with active rheumatoid arthritis w... 2012-12-14 due-trials
Reported results 2007-000897-21 A multi-center, double-blind, historical control, randomized conversion to monotherapy study with Keppra XR for treatment of partial onset seizures 2009-09-14 due-trials
Reported results 2007-000899-17 An open-label, long-term follow-up study with Keppra XR for treatment of partial-onset seizures 2010-03-31 due-trials
Reported results 2007-001913-41 A phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclo... 2009-11-25 due-trials
Reported results 2007-002566-35 A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients ... 2009-08-17 due-trials
Reported results 2007-002589-37 A Phase IIb, Multi-center, Open-label, Follow-up Study to Assess the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease Who Particip... 2011-12-28 due-trials
Reported results 2007-002716-26 A phase IIIb, multinational, open-label, follow-on trial to C87085 designed to assess the long-term safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti TNF alpha monoclonal ant... 2014-12-22 due-trials
Ongoing 2007-003239-21 A phase IIIb, open label, randomized, exploratory clinical study exploring efficacy, safety and patients’ satisfaction with Certolizumab pegol treatment in moderate to severe Crohn’s disease when trea... not-yet-due
Trial is outside EEC, and reported results 2007-003458-28 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months With Sy... bad-data
Reported results 2007-003517-13 Open-label, single-arm, multi-center, pharmacokinetic, safety and tolerability study of levetiracetam intravenous infusion in children (1 month to 4 years old) with epilepsy. 2010-03-11 due-trials
Reported results 2007-005288-86 A Phase IIIb, open-label, run-in and double-blind, placebo-controlled, randomized study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with stable-dose methotrexa... 2011-03-01 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-005439-27 A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400mg/day Monotherapy in Subjects with Partial-onset Seizures 2012-12-06 bad-data
Trial is partly outside EEC, and reported results 2007-005440-25 A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-onset Seizures 2015-02-04 bad-data
Reported results Terminated 2007-006558-24 PHASE 3B, OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE PRACTICABILITY AND TOLERABILITY OF SWITCHING SUBJECTS OVERNIGHT FROM PRAMIPEXOLE OR ROPINIROLE TO ROTIGOTINE TRANSDERMAL PATCH AND ITS EFFECT ON S... 2008-03-31 due-trials
Reported results 2008-000144-14 An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (≥ 16 to 75... 2010-05-17 due-trials
Reported results 2008-000145-58 An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (#8805; 16 ... 2010-05-17 due-trials
Reported results 2008-001433-98 An open-label, multinational, multicenter, follow-up study to evaluate the long-term safety and efficacy of brivaracetam, used at a flexible dose up to a maximum of 150 mg/day, in subjects aged 16 yea... 2018-03-20 due-trials
Reported results 2008-004714-27 A Multicenter, Open-label, Four-arm, Randomized trial, Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic... 2012-07-18 due-trials
Reported results 2008-005427-28 A Phase IIIb, multicenter study with a 12-week double-blind, placebo-controlled, randomized period followed by an open-label, extension phase to evaluate the safety and efficacy of certolizumab pegol ... 2011-03-08 due-trials
Exempt, with results 2009-010813-57 A multicenter, randomized, double-blind, placebo-controlled, single dose study to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of intravenous and subcutaneous CDP6038 in ma... 2010-09-20 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2009-011181-28 AN OPEN-LABEL, MULTICENTER, MULTINATIONAL STUDY OF LACOSAMIDE AS FIRST ADD-ON ANTIEPILEPTIC DRUG (AED) TREATMENT IN SUBJECTS WITH PARTIAL-ONSET SEIZURES 2013-08-09 bad-data
Reported results 2009-011719-19 PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXIAL SPA) 2015-08-18 due-trials
Reported results 2009-011720-59 Estudio de fase III, multicéntrico, aleatorizado, doble ciego, en grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de certolizumab pegol en sujetos con artritis psoriá... 2015-08-24 due-trials
Reported results 2009-013758-33 MULTICENTER STUDY WITH A 16-WEEK DOUBLE-BLIND, PLACEBO-CONTROLLED (DURING THE INITIAL 2 WEEKS) RANDOMIZED PERIOD, FOLLOWED BY A 24-WEEK OPEN LABEL EXTENSION TO ASSESS MAGNETIC RESONANCE IMAGE-VERIFIED... 2013-05-02 due-trials
Ongoing 2009-014341-84 Non-GI: A multi site, open-label, interventional Pilot study assessing the switch from oral treatment to rotigotine transdermal patch (Neupro) in Parkinson's disease patients with identified gastroint... not-yet-due
Trial is outside EEC, and reported results 2009-018027-33 A multicenter, open-label study to assess the pharmacokinetics, safety and efficacy of certolizumab pegol in children and adolescents with moderately to severely active polyarticular-course juvenile i... bad-data
Reported results 2010-018563-41 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FOUR 12-WEEK TREATMENT CYCLES (48 WEEKS TOTAL) OF EPRATUZUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS ... 2015-05-15 due-trials
Reported results 2010-018565-26 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FOUR 12-WEEK TREATMENT CYCLES (48 WEEKS TOTAL) OF EPRATUZUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS ... 2015-06-03 due-trials
Reported results 2010-019268-35 A MULTI-CENTER, OPEN-LABEL STUDY TO EVALUATE THE TOLERABILITY, SAFETY AND EFFICACY OF LACOSAMIDE (200 mg - 400mg/day) AS ADD-ON THERAPY FOR PATIENTS WITH PARTIAL ONSET EPILEPSY USING A FLEXIBLE DOSE-E... 2011-12-19 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-019361-28 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS (≥16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES 2014-05-22 bad-data
Trial is partly outside EEC, and reported results 2010-019765-28 A MULTICENTER, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, POSITIVE CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LACOSAMIDE (200 TO 600MG/DAY) TO CONTROLLED RELEASE CARBAMAZEPINE (400 TO 1200MG... 2015-08-07 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-020345-27 AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY 2019-04-19 bad-data
Reported results 2010-020839-39 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY WITH AN ACTIVE COMPARATOR TO EVALUATE THE EFFICACY AND SAFETY OF CDP6038 ADMINISTERED SUBCUTANEOUSLY FOR 12 WEEKS TO SUBJECTS WITH AC... 2012-06-29 due-trials
Reported results 2010-020859-30 A phase 3, multicenter, open-label, extension study to assess the safety and tolerability of Epratuzumab treatment in systemic lupus erythematosus subjects (EMBODY 4) 2016-02-19 due-trials
Trial is partly outside EEC, and reported results 2010-021238-74 A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, FOLLOW UP STUDY EVALUATING THE LONG TERM SAFETY OF LACOSAMIDE (200 TO 600MG/DAY) IN COMPARISON WITH CARBAMAZEPINE (400 TO 1200MG/DAY), USED AS MONOTHERAPY... 2017-01-03 bad-data
Reported results 2010-021394-37 Estudio multicéntrico, doble ciego, controlado con placebo, de grupos paralelos, fase IV para evaluar el efecto de rotigotina sobre los síntomas no motores en pacientes con enfermedad de Parkinson idi... 2013-01-25 due-trials
Reported results Terminated 2010-022224-77 A PHASE 2 MULTI-CENTER, OPEN-LABEL, FOLLOW-UP STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF CDP6038 ADMINISTERED SUBCUTANEOUSLY TO SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO COMPLETED STUDY ... 2013-07-31 due-trials
Reported results 2010-022534-84 A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE HORMONE AND LIPID LEVELS IN MALE SUBJECTS WITH PARTIAL-ONSET SEIZURES AFTER A SWITCH OF TREATMENT FROM CARBAMAZEPINE AS ADJUNCTIVE TREATMENT TO ... 2013-12-03 due-trials
Reported results 2011-000053-23 Multicenter, double-blind, placebo-controlled, two-arm, randomized, parallel, treatment intervention, sleep lab phase 4 study to assess the effect of rotigotine on nocturnal blood pressure in patients... 2012-06-21 due-trials
Reported results Terminated 2011-000056-42 A MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECTS OF ROTIGOTINE ON SLEEP EFFICIENCY IN PATIENTS WITH ADVANCED PARKINSON’S DISEASE 2012-11-21 due-trials
Trial is partly outside EEC, and reported results 2011-000374-60 Estudio de seguimiento, multicéntrico, abierto, a largo plazo, para evaluar la seguridad y la eficacia de brivaracetam como tratamiento adyuvante en pacientes pediátricos con epilepsia Open-label, si... 2022-02-03 bad-data
Completed, but no date, and reported results 2011-000385-35 MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE PREDICTABILITY OF EARLY RESPONSE TO CERTOLIZUMAB PEGOL (IN COMBINATION WITH METHOTREXATE) AS CONFIRMED AT WEEK 52 IN SUBJECTS WITH MODERATE-SEVERE RHEUMAT... bad-data
Trial is partly outside EEC, and reported results 2011-001558-27 A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LACOSAMIDE (LCM) ORAL SOLUTION (SYRUP) AS ADJUNCTIVE THERAPY IN CHILDREN WITH PARTIAL ONSET SEIZURES bad-data
Trial is partly outside EEC, and reported results 2011-001559-35 AN OPEN-LABEL STUDY TO DETERMINE SAFETY, TOLERABILITY, AND EFFICACY OF LONG-TERM ORAL LACOSAMIDE (LCM) AS ADJUNCTIVE THERAPY IN CHILDREN WITH EPILEPSY 2021-05-18 bad-data
Reported results 2011-001729-25 A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of certolizumab pegol in combination with methotrexate for inducing and sustaining clinical respo... 2015-09-10 due-trials
Reported results 2011-002067-20 A multicenter, single blind, randomized parallel group study to assess the short and long term efficacy of certolizumab pegol plus methotrexate compared with adalimumab plus methotrexate in subjects... 2016-01-13 due-trials
Reported results 2011-002461-37 A PROSPECTIVE, MULTINATIONAL, OPEN-LABEL, SINGLE-ARM, EXPLORATIVE STUDY TO EVALUATE THE TOLERABILITY AND EFFICACY OF LACOSAMIDE WHEN ADDED TO LEVETIRACETAM WITH WITHDRAWAL OF THE CONCOMITANT SODIUM CH... 2014-01-10 due-trials
Reported results Terminated 2011-002517-11 A multi-centre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetic of olokizumab administered subcutaneously to subjects with modera... 2012-10-18 due-trials
Trial is partly outside EEC, and reported results 2011-003100-21 A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLO... 2019-06-05 bad-data
Reported results 2011-003486-15 A multi-center, randomized, double-blind, placebo-controlled, parallel group, polysomnography study to investigate safety and efficacy of the rotigotine transdermal patch in subjects with Restless L... 2013-10-29 due-trials
Reported results 2011-005177-23 An Open-Label, Multicenter, Single-Arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects with Epilepsy Switching from Levetiracetam to Brivaracetam due to Nonpsychoti... 2013-11-15 due-trials
Reported results 2012-000827-42 AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY 2016-08-09 due-trials
Trial is partly outside EEC, and reported results 2012-001446-18 A MULTI-CENTER, OPEN-LABEL, EXPLORATORY STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS ≥1 MONTH TO <18 YEARS WITH EPILEPSY SYNDROMES ASSOCIATED WITH GENER... 2018-05-25 bad-data
Trial is partly outside EEC, and reported results 2012-001770-29 AN OPEN-LABEL, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH... 2023-03-30 bad-data
Reported results 2012-002608-42 A Multicenter, Multinational, Double-blind, Placebo-controlled, 2-arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain 2014-01-30 due-trials
Reported results 2012-002840-26 A MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PHASE 4 STUDY TO EVALUATE THE EFFICACY OF ROTIGOTINE ON PARKINSON’S DISEASE-ASSOCIATED APATHY, MOTOR SYMPTOMS, AND MOOD STUDIO... 2014-03-04 due-trials
Trial is partly outside EEC, and reported results 2012-004996-38 A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS WITH EPILEPSY >=4 YEARS TO <17 ... 2017-01-24 bad-data
Trial is partly outside EEC, and reported results 2012-005012-26 A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS WITH EPILEPSY WITH PARTIAL ONSET SEIZURES 2022-04-13 bad-data
Trial is partly outside EEC, and reported results 2013-000717-20 A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS WITH EPILEPSY >=1 MONTH TO <4 Y... 2020-05-28 bad-data
Exempt, with results 2013-003812-30 A MULTICENTER POSTMARKETING STUDY TO EVALUATE THE PLACENTAL TRANSFER OF CERTOLIZUMAB PEGOL IN PREGNANT WOMEN RECEIVING TREATMENT WITH CIMZIA® (CERTOLIZUMAB PEGOL) not-yet-due
Trial is outside EEC, and reported results 2014-002629-36 A multicenter, open-label study to investigate the pharmacokinetics of commercial lacosamide oral formulation as therapy in children (aged 1 month to 17 years) with epilepsy. bad-data
Trial is outside EEC, and reported results 2014-002713-32 A Multi-Center, Open-label, Randomized Study to Evaluate the Long Term Effectiveness of Levetiracetam as Monotherapy in Comparison With Oxcarbazepine in Subjects With Newly or Recently Diagnosed Parti... bad-data
Reported results 2014-003294-42 A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF INTRAVENOUS LACOSAMIDE IN CHILDREN (≥1 MONTH TO <17 YEARS OF AGE) WITH EPILEPSY 2019-06-28 due-trials
Reported results 2014-003307-30 A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Multiple Doses of UCB4940 Administered as Add-On to Certolizumab Pegol Th... 2017-04-19 due-trials
Reported results 2014-003330-12 A double-blind, randomized, placebo-controlled study of the efficacy, safety/tolerability, and pharmacokinetic profile of UCB0942 in adult patients with highly drug-resistant focal epilepsy 2017-07-18 due-trials
Reported results 2014-003486-14 A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-group Study Followed by a Dose-blind Period and Open-label Follow-up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects wi... 2018-09-12 due-trials
Reported results 2014-003492-36 A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- And Active-Controlled Study Followed By A Placebo-Controlled Maintenance Period And Open-Label Follow-Up To Evaluate The Effi... 2018-12-17 due-trials
Reported results 2014-003513-28 A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group Study Followed by a Dose-blind Period and Open Label Follow-up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects wi... 2018-10-24 due-trials
Trial is outside EEC, and reported results 2014-003622-41 A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Uncontroll... bad-data
Trial is outside EEC, and reported results 2014-004333-57 A Double-blind, Randomized, Placebo-controlled 5 Parallel Groups, Confirmatory Trial on the Efficacy and Safety of Levetiracetam used as add-on Therapy at doses of 0.5 to 3 g/day in Patients From 16 t... bad-data
Trial is outside EEC, and reported results 2014-004334-26 A Multicenter, Open, Long-term Follow-up Study to Evaluate the Safety and Efficacy of L059 (Levetiracetam) at Individual Optimal Dose Ranging From 500 to 3000 mg/Day in Twice Daily Administration in S... bad-data
Trial is outside EEC, and reported results 2014-004335-39 An Open Label, Single-Arm, Multi-Center Study on the Efficacy, Safety and Pharmacokinetics of Levetiracetam in Pediatric Patients (4 to 16 Years) With Partial Seizures Despite Treatment With 1 or 2 An... bad-data
Trial is outside EEC, and reported results 2014-004354-34 A 26-week, multi-center, open-label study to investigate the efficacy and safety of CDP870 in active Crohn’s disease patients, who showed clinical efficacy in a remission induction study (Study C87037... bad-data
Trial is outside EEC, and reported results 2014-004375-23 An open-label extension study to assess the safety and seizure frequency associated with long-term oral lacosamide for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathi... bad-data
Trial is outside EEC, and reported results 2014-004376-39 An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epi... bad-data
Trial is outside EEC, and reported results 2014-004377-16 An Open-label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Levetiracetam Used as Monotherapy in Newly or Recently Diagnosed Epilepsy Patients Aged Older Than or Equal to 16 Ye... bad-data
Trial is outside EEC, and reported results 2014-004378-40 A Multicenter, Open-label Trial to Assess the Safety and Tolerability of a Single Intravenous Loading Dose of Lacosamide Followed by Oral Lacosamide Maintenance as Adjunctive Therapy in Subjects With ... bad-data
Trial is outside EEC, and reported results 2014-004379-22 An Open-Label Pilot Study to Assess the Safety of Oral Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy bad-data
Trial is outside EEC, and reported results 2014-004381-24 A Phase 2, Open-label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease (NURTURE Study) bad-data
Trial is outside EEC, and reported results 2014-004382-25 An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With Levetiracetam in Japanese Patients (≥4 to <16 Years) With Uncontrolled Generalized Tonic-c... bad-data
Trial is outside EEC, and reported results 2014-004383-37 A Multicenter, Open-Label, 2-Group, Dose Escalation Study of Monotherapy Administration of Rotigotine in Pediatric Subjects With Idiopathic Restless Legs Syndrome bad-data
Trial is outside EEC, and reported results 2014-004384-21 A Multicenter, Open-label Extension Trial to Assess the Long-term Safety and Tolerability of Lacosamide as Adjunctive Therapy in Subjects With Partial-onset Seizures bad-data
Trial is outside EEC, and reported results 2014-004396-23 A 19-week, Randomized, Double-blind, Multicenter, Placebo-controlled Safety Study to Evaluate the Cognitive and Neuropsychological Effects of Levetiracetam 20-60 mg/kg/day, Divided in Twice Daily Dosi... bad-data
Trial is outside EEC, and reported results 2014-004397-42 An open-label, multi-center, follow-up trial to evaluate the long-term safety and efficacy of brivaracetam used as adjunctive treatment at a flexible dose up to a maximum of 200 mg/day in subjects age... bad-data
Trial is outside EEC, and reported results 2014-004398-18 An Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral SPM 927 in Patients With Partial Seizures bad-data
Trial is outside EEC, and reported results 2014-004399-42 A Phase II, Multi-center, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Assess the Safety and Efficacy of CDP870/Certolizumab Pegol, Dosed Subcutaneously in Patients With Ac... bad-data
Trial is outside EEC, and reported results 2014-004400-30 A multi-center, open-label study to investigate the efficacy and safety of CDP870 in active Crohn’s Disease patients, who showed no clinical efficacy in a remission induction study (Study C87037) but ... bad-data
Trial is outside EEC, and reported results 2014-004401-32 A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With Oral Levetiracetam, in Epilepsy Patients Aged ≥16 Years, With General... bad-data
Trial is outside EEC, and reported results 2014-004402-15 A Randomized, Open-label, Parallel Group, Multi-center, Comparative, Phase IV Trial of Levetiracetam (LEV) Versus Topiramate (TPM) as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects Wi... bad-data
Reported results 2014-004523-51 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UCB5857 OVER 12 WEEKS IN SUBJECTS WITH PRIMARY SJOGREN?S SYNDROME ESTUDIO PRUEBA DE CON... 2017-09-27 due-trials
Trial is outside EEC, and reported results 2015-000205-39 A Multi-Center, Randomized, Double Blind, Placebo Controlled Parallel Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation b.i.d Dosing in Children Aged 1 to < 6 Years S... bad-data
Reported results 2015-000339-34 MULTICENTER, OPEN-LABEL (PART A) FOLLOWED BY A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY (PART B) TO EVALUATE MAINTENANCE OF REMISSION IN SUBJECTS WITH ACTIVE AXIAL SPONDYLOAR... 2019-04-23 due-trials
Reported results 2015-001268-20 AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF UCB0942 WHEN USED AS ADJUNCTIVE THERAPY FOR PARTIAL-ONSET SEIZURES IN ADULT SUBJECTS WITH HI... 2020-11-24 due-trials
Reported results 2015-001549-96 A MULTICENTER, OPEN-LABEL, FOLLOW-UP STUDY TO ASSESS THE LONG-TERM USE OF LACOSAMIDE (FLEXIBLE DOSE FROM 200 TO 600 MG/DAY) USED AS MONOTHERAPY IN SUBJECTS WHO COMPLETED SP0994 AND RECEIVED LACOSAMID... 2020-02-06 due-trials
Reported results 2015-001894-41 PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXSPA) WITHOUT X-RAY EVI... 2020-05-05 due-trials
Listed as ongoing, but also has a completion date and reported results 2015-002756-27 A multicenter, open-label, single-arm study to evaluate the pharmacokinetics, efficacy, and safety of brivaracetam in neonates with repeated electroencephalographic seizures 2021-12-23 bad-data
Exempt, with results 2015-002900-10 AN OPEN-LABEL EXPLORATORY STUDY OF UCB5857 IN SUBJECTS WITH ACTIVATED PHOSPHOINOSITIDE 3 KINASE (PI3K) DELTA SYNDROME (APDS) 2018-01-23 not-yet-due
Reported results 2015-003984-12 A MULTICENTER, OPEN-LABEL, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF UCB7665 IN SUBJECTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA 2019-02-04 due-trials
Reported results 2015-004457-40 A MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY FOLLOWED BY AN OBSERVATIONAL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN SUBJE... 2019-11-19 due-trials
Trial is outside EEC, and reported results 2015-004586-84 A multicenter, open-label, randomized, parallel-group, active-controlled study comparing the efficacy and safety of Levetiracetam to Carbamazepine used as monotherapy in subjects (≥16 years) newly or ... bad-data
Reported results 2015-005541-30 AN OPEN-LABEL, EXPLORATORY, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF UCB5857 IN SUBJECTS WITH ACTIVATED PHOSPHOINOSITIDE 3 KINASE (... 2018-12-13 due-trials
Reported results 2016-000343-14 Multicenter, Open-Label Study To Assess The Effects Of Certolizumab Pegol On The Reduction Of Anterior Uveitis Flares In Axial Spondyloarthritis Subjects With A History Of Anterior Uveitis (C-VIEW) 2020-01-23 due-trials
Reported results 2016-000393-37 A MULTICENTER, SUBJECT-BLIND, INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY/TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE INTRAVENOUS DOSES OF BIMEKIZUMAB (... 2016-09-02 due-trials
Reported results Terminated 2016-000420-26 A MULTICENTER, SUBJECT-BLIND, INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF AN IV LOADING DOSE FOLLOWED BY SC ADMINIST... 2018-05-30 due-trials
Trial is outside EEC, and reported results 2016-000635-40 AN OPEN-LABEL, LONG-TERM FOLLOW-UP STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND EFFICACY OF ROTIGOTINE TRANSDERMAL SYSTEM AS MONOTHERAPY IN ADOLESCENTS WITH RESTLESS LEGS SYNDROME bad-data
Reported results 2016-001102-42 A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLI... 2018-08-30 due-trials
Reported results 2016-001103-23 A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ACTIVE PSORIATIC ARTHRITIS 2018-07-16 due-trials
Reported results 2016-001891-31 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinectics, and Pharmacodynamics of Bimekizumab in Adult subjec... 2017-07-10 due-trials
Reported results 2016-001892-57 A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects with Moderate to Se... 2018-09-25 due-trials
Reported results 2016-002107-26 AN OPEN-LABEL ADAPTIVE STUDY FOR THE ASSESSMENT OF SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MULTIPLE DOSES OF RADIPRODIL IN SUBJECTS WITH DRUG-RESISTANT INFANTILE SPASMS 2018-10-02 due-trials
Completed, but no date, and reported results Terminated 2016-002368-15 A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderate t... bad-data
Listed as ongoing, but also has a completion date and reported results 2016-002411-17 A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects with Chronic Inf... 2021-03-31 bad-data
Reported results 2016-002452-25 A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF INTRAVENOUS BRIVARACETAM IN SUBJECTS =1 MONTH TO <16 YEARS OF AGE WITH EPILEPSY STUDIO MULTICENTRICO IN... 2020-11-04 due-trials
Reported results 2016-002698-36 A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects with Moderate to Sever... 2018-08-06 due-trials
Trial is outside EEC, and reported results 2016-002879-96 An open-label, multicenter, long-term, follow-up study in Japan to evaluate the safety, tolerability, and efficacy of adjunctive treatment with oral L059 (levetiracetam) in epilepsy subjects with gene... bad-data
Completed, but no date, and reported results Terminated 2016-002934-57 A multicenter, 48-week, open-label extension study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis. bad-data
Reported results 2016-003392-22 A Phase 3, Multicenter, Randomized, Double-Blind Study with an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of B... 2020-02-26 due-trials
Reported results 2016-003425-42 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to ... 2019-12-13 due-trials
Reported results 2016-003426-16 A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study with an Initial Treatment Period Followed by a Randomized-Withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult S... 2020-01-07 due-trials
Listed as ongoing, but also has a completion date 2016-003427-30 A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis 2023-11-14 bad-data
Reported results 2016-003522-16 A PHASE 2 MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RA101495 IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBI... 2018-03-28 due-trials
Listed as ongoing, but also has a completion date and reported results 2016-003523-34 A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects with Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study 2021-10-26 bad-data
Reported results 2017-000892-10 A Phase 2 Multicenter, Investigator-blind, Subject-blind, Placebo-controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects with Moderate to Severe Hidradenitis Suppura... 2019-02-21 due-trials
Reported results 2017-000957-37 A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects with Active Ankylosin... 2020-05-25 due-trials
Listed as ongoing, but also has a completion date and reported results 2017-001002-15 A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects with Ankylosing Spondylitis 2022-10-19 bad-data
Reported results 2017-001003-74 A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects with Psoriatic Arthritis 2020-10-29 due-trials
Listed as ongoing, but also has a completion date and reported results 2017-002322-20 A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSO... 2022-07-11 bad-data
Listed as ongoing, but also has a completion date and reported results 2017-002804-29 A MULTICENTER, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS 2022-02-14 bad-data
Listed as ongoing, but also has a completion date and reported results 2017-003064-13 A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS 2023-04-17 bad-data
Listed as ongoing, but also has a completion date and reported results 2017-003065-95 A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS 2022-08-08 bad-data
Reported results 2017-003200-48 A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug- Resist... 2020-02-26 due-trials
Listed as ongoing, but also has a completion date and reported results 2017-003241-26 An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug-Resistant Epilepsy 2020-12-11 bad-data
Listed as ongoing, but also has a completion date and reported results 2017-003784-35 A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoria... 2023-08-09 bad-data
Exempt, with results 2017-004807-31 A 2-Stage, Multicenter, Randomized, Placebo-Controlled Study to Evaluate Safety/Tolerability, Pharmacokinetics, and Efficacy of UCB7858 in Adult Kidney Transplant Recipients With Chronic Allograft Inj... 2022-05-04 not-yet-due
Trial is outside EEC, and reported results 2017-005025-20 An open-label, multicenter study to assess the safety of certolizumab pegol in children and adolescents with active Crohn's Disease who completed C87035 or who were terminated from C87035 when the stu... bad-data
Trial is outside EEC, and reported results 2018-001445-13 A Remote, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine Transdermal System in Adolescent Subjects With Idiopathic Restless Legs Syndrome bad-data
Reported results 2018-002303-33 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects Wi... 2020-09-28 due-trials
Completed, but no date, and reported results Terminated 2018-003956-19 Phase 3, Multicenter, Open-Label, Single-Arm Study to Confirm the Safety and Efficacy of Zilucoplan in Treatment-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria bad-data
Listed as ongoing, but also has a completion date and reported results 2018-004392-12 An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 2021-11-10 bad-data
Other 2018-004725-86 A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS not-yet-due
Listed as ongoing, but also has a completion date and reported results 2019-000883-40 An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) 2022-12-23 bad-data
Listed as ongoing, but also has a completion date and reported results 2019-000884-26 A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic P... 2022-09-27 bad-data
Listed as ongoing, but also has a completion date and reported results 2019-000968-18 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis. 2021-10-26 bad-data
Listed as ongoing, but also has a completion date and reported results 2019-000969-21 A Randomized, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis 2021-09-01 bad-data
Trial is outside EEC, and reported results 2019-001203-21 A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam in Subjects (>=16 to 80 Years of Age) With Partial Seiz... bad-data
Reported results 2019-001497-29 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Immune-Mediated Necrotizing Myopathy 2021-06-14 due-trials
Listed as ongoing, but also has a completion date and reported results 2019-001564-30 A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis 2021-12-30 bad-data
Other 2019-001565-33 A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis not-yet-due
Listed as ongoing, but also has a completion date and reported results 2019-002550-23 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa ... 2023-02-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2019-002551-42 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa 2022-09-28 bad-data
Exempt 2019-002598-78 A Phase 1/2 Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors not-yet-due
Listed as ongoing, but also has a completion date 2019-003406-27 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Sy... 2024-06-04 bad-data
Ongoing 2019-003407-35 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Sy... not-yet-due
Ongoing 2019-003409-83 A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus not-yet-due
Listed as ongoing, but also has a completion date and reported results 2019-003451-11 A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic P... 2022-05-05 bad-data
Ongoing 2019-004163-47 A Multicenter, Open-Label Extension Study to Asses the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosin... not-yet-due
Trial is outside EEC, and reported results 2019-004756-11 A multi-center, open-label, uncontrolled, long-term, extension study to evaluate the safety and efficacy of Lacosamide as adjunctive therapy in Japanese and Chinese adults with partial-onset seizures ... bad-data
Listed as ongoing, but also has a completion date 2019-004778-25 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Gliom... 2024-04-30 bad-data
Trial is outside EEC 2020-001066-10 A Multicenter, Open-Label, Randomized, Active Comparator Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures bad-data
Other 2020-001478-30 A Multicenter, Open-Label, Follow-Up Study to Assess the Long-Term Use of Oral Lacosamide in Study Participants Who Completed EP0034 or SP848 and Received Lacosamide Treatment not-yet-due
Trial is partly outside EEC 2020-001724-34 A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis bad-data
Trial is partly outside EEC 2020-002750-24 A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2-Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safet... bad-data
Trial is partly outside EEC 2020-002769-33 A Multicenter, Open-Label, Single-Arm Study to Evaluate Long-Term Safety, Tolerability, and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juven... bad-data
Listed as ongoing, but also has a completion date 2020-003230-20 An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis 2024-01-25 bad-data
Listed as ongoing, but also has a completion date 2020-003265-19 A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson'... 2024-09-06 bad-data
Exempt 2020-003639-41 Phase 1/2A, randomized, placebo-controlled, single-ascending dose (Part A, participant- and investigator-blind) and repeated-dose (Part B, participant-, investigator-, and sponsor-blind) study to inve... 2024-06-06 not-yet-due
Ongoing 2020-003664-29 Open-Label, Single-Arm, Multicenter Study to Evaluate Long-Term Safety and Tolerability of Brivaracetam Used as Adjunctive Treatment in Pediatric Study Participants With Epilepsy not-yet-due
Ongoing 2020-004179-42 A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa not-yet-due
Other 2020-005829-88 A PATIENT- AND INVESTIGATOR-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BEPRANEMAB (UCB0107) IN STUDY PARTICIPANTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE ... not-yet-due
Other 2021-000352-19 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants Wit... not-yet-due
Other 2021-002637-42 An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizu... not-yet-due
Other 2021-002686-18 A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older W... not-yet-due
Trial is outside EEC, and reported results 2021-003372-13 An Open-Label, Single-Arm, Multicenter Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging from 1 Month to Less Than 4 Years of Ag... bad-data
Trial is outside EEC, and reported results 2021-003403-18 A Remote, Open-Label, Long-Term, Follow-up Study to Determine the Safety, Tolerability, and Efficacy of Rotigotine Transdermal System as Monotherapy in Adolescents With Restless Legs Syndrome bad-data
Trial is outside EEC, and reported results 2022-002523-36 A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, TOLERABILITY, AND SAFETY OF A SINGLE DOSE OF STACCATO ALPRAZOLAM IN ADOLESCENT STUDY PARTICIPANTS WITH EPILEPSY bad-data
Listed as ongoing, but also has a completion date 2022-003870-21 An open-label, crossover study to evaluate rozanolixizumab self-administration by study participants with generalized Myasthenia Gravis Studio crossover in aperto per valutare l’auto-somministrazio... 2024-04-18 bad-data